Reference
Sverak P, et al. Bevacizumab for Hearing Preservation in Neurofibromatosis Type 2: Emphasis on Patient-Reported Outcomes and Toxicities. Otolaryngology - Head and Neck Surgery 160: 526-532, No. 3, Mar 2019. Available from: URL: http://doi.org/10.1177/0194599818809085 - USA
Rights and permissions
About this article
Cite this article
Bevacizumab. Reactions Weekly 1748, 86 (2019). https://doi.org/10.1007/s40278-019-60002-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-60002-3